April 29th 2024
Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.
February 1st 2024
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Safety of T-DM1/Temozolomide for The Prevention of HER2-Breast Cancer Associated Brain Mets
December 11th 2021Alexandra S. Zimmer, MD, discusses the safety of the combination of the T-DM1 ado-trastuzumab emtansine and temozolomide, for the prevention of further brain metastases in patients with HER2-positive breast cancer with brain metastases.
Watch
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup Analysis
December 9th 2021Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Read More
Updated Analysis Shows Improved OS for Pyrotinib Over Lapatinib in HER2-Positive Breast Cancer
December 9th 2021Updated data from the PHOEBE trial show that pyrotinib plus capecitabine improved overall survival in patients with HER2-positive breast cancer compared with lapatinib plus capecitabine.
Read More
CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer
December 8th 2021A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.
Read More
Further Exploration of the HER2CLIMB Regimen in Pretreated HER2 Breast Cancer
October 27th 2021Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.
Watch
Novel Device May Predict Response to Therapy in Patients With Early Breast Cancer
October 27th 2021Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.
Read More
Data Supporting Trastuzumab/Pertuzumab Use In HER2+ Breast Cancer with Leptomeningeal Disease
October 7th 2021Kamran A. Ahmed, MD, discusses the data leading up to the phase 1/2 study of radiotherapy followed by intrathecal trastuzumab and pertuzumab for the management of HER2-positive breast cancer with leptomeningeal disease and what impact the study may have on the community oncology space.
Watch
Differences Between the Global and Asian HER2+ BC Cohorts in the KAMILLA Trial
October 2nd 2021Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Watch
When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.
Read More
Trastuzumab Deruxtecan Shows Efficacy Over T-DM1 in HER2+ Breast Cancer
September 18th 2021Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.
Read More
Tucatinib Detectable in Cerebral Spinal Fluid and Plasma of Patients With HER2+ BC
September 2nd 2021Erica Stringer-Reasor, MD discusses the results of a phase 2 study examining the combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive breast cancer with leptomeningeal metastasis.
Read More
HER2CLIMB Regimen Explored in HER2-Breast Cancer with Leptomeningeal Metastases
August 26th 2021In an Interview with Targeted Oncology, Debasish Tripathy, MD, discusses the triplet regimen for HER2+ breast cancer with leptomeningeal metastases in greater detail along with its broader clinical applications.
Read More
Online Tool PREDICT+ Underestimates Survival in HER2+ Breast Cancer
August 26th 2021In an interview with Targeted Oncology™, lead study author Elisa Agostinetto, MD, of the Istituto Clinico Humanitas in Rozzano, Milan, Italy, discussed the accuracy of PREDICT+ in HER2-positive breast cancer in greater detail and its clinical implications.
Read More
With the development of anti-HER2 antibody-drug conjugates, clinicians are looking to expand the number of patients they can treat. Now, a new study shows that HER2-low-positive tumors can be identified as a new subgroup to help treat patients with HER2-positive breast cancer.
Read More
Trastuzumab and Chemotherapy Could Reduce Early-Stage HER2-Positive Breast Cancer Deaths by a Third
August 10th 2021The addition of trastuzumab to chemotherapy for the treatment of early-stage, HER2-positive breast cancer helps to reduce disease recurrence and can potentially reduce the mortality from breast cancer by a third worldwide.
Read More
Tucatinib, Trastuzumab, and Capecitabine Improve OS, PFS in HER+ Breast Cancer
August 9th 2021Guiseppe Curigliano, MD, discusses the design and results of the HER2CLIMB-02 study which evaluated the efficacy of tucatinib in combination with trastuzumab and capecitabine in HER2-positive breast cancer patients with and without brain metastases compared to placebo.
Watch
A highly statistically significant improvement in progression-free survival has been observed with the HER2 monoclonal antibody trastuzumab deruxtecan treatment compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer, meeting the primary end point of the phase 3 DESTINY-Breast03 trial.
Read More
Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
July 31st 2021Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Watch